Hydroxyurea (HU) enhances fetal hemoglobin (Hb) production. An increase in total Hb level has been repeatedly reported during HU treatment in patients with sickle cell disease and in several patients with -thalassemia intermedia. Effects in patients with -thalassemia major are controversial. We now report a marked elevation of total Hb levels with HU that permitted regular transfusions to be stopped in seven transfusion-dependent -thalassemic children. The median follow-up was 19 + 3 months (range: 13-21). We conclude that HU can eliminate transfusional needs in children with -thalassemia major, which could be particularly useful in countries like Algeria, where supplies of blood or chelating agents are limited.
Introduction
Hydroxyurea (HU) promotes fetal hemoglobin (HbF) production via a reactivation of -genes, thanks to molecular mechanisms that are not yet elucidated. The clinical benefit induced by this compound in patients affected with sickle cell disease has been repeatedly demonstrated [1, 2] . A significant benefit could also be expected in patients withthalassemia, since the imbalance in globin chains could be ameliorated by the newly synthesized -chains being able to neutralize the excess -chains, which could partially correct ineffective erythropoiesis. Clinical and hematological improvements have been reported in patients with thalassemia intermedia [3] [4] [5] [6] [7] [8] , but responses in patients with thalassemia major are controversial [5, 9] . We have followed up seven transfusion-dependent -thalassemic children, 6 of them with severe transfusional complications, and have treated them with hydroxyurea in the hope that this drug could reduce transfusional needs.
Study design
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From Seven children were included, 3 pairs of siblings and one single child. Their main clinical and biological characteristics are given in Table 1 . As blood supplies are limited in Algeria, the targeted post-transfusional hemoglobin level is only 7-9 g/dl. Six patients had major transfusional complications: transfusion-induced anaphylactic reactions (patient 1); severe chills and fever (patients 2, 6); post-transfusional hemochromatosis (ferritin level: 3500 ng/ml) with cutaneous, hepatic and gonadic manifestations (patient 3); multiple red cell alloimmunization (patient 4); lack of venous access (patient 5). Patient 1 also had painful retroperitoneal masses, and scintigraphic and tomodensitometric studies attributed these to extramedullary hematopoiesis. The parents of child 1 requested HU treatment for their other affected child (patient 7). The protocol was approved by the Internal Review Board, and all families gave their informed consent. Each month we determined complete blood counts (using the Sysmex 2000 counter) and biochemical parameters including BUN, creatinine, AST, ALT and alkaline phosphatase. HbF levels were calculated with the alkali denaturation technique (modified Betke method).
Results and discussion
The median follow-up was 19 months (13-21) in October 2002. Total Hb increased in all patients, as indicated in Fig.1 . In conclusion, our series agrees with previous studies reporting clinical and hematological improvement with HU, and regression of extramedullary hematopoietic masses inthalassemia intermedia patients [7, 10] . HU has already been successfully used in an irregularly transfused patient with -thalassemia major [11] . This report is, to our knowledge, the first one showing sustained discontinuation of transfusions after beginning treatment with HU in 5 children affected with severe -thalassemia major. It is possible that the effect of HU on -globin expression is associated with the type of thalassemic mutation or the G -158 C>T polymorphism (Xmn I). It is notable that our patients had similar increases in Hb level whatever their genotypes ( 0 or + mutations, Xmn I polymorphism). In addition, the increase in total Hb level in our patients is probably not completely explained by the sole increase in
Hb levels under HU
HbF from 91 to 98%. A reduction in ineffective erythropoiesis is strongly suggested by the marked decrease in the number of circulating erythroblasts. -thalassemia is a very heterogeneous group of diseases related to multiple mutations, and our observation cannot be generalized prematurely to all -thalassemic syndromes. Since these initial promising results, seven more transfusion-dependent -thalassemic children have been treated with HU. After only some months of follow-up, transfusions have been stopped in 2, spaced out in 2 (one every 2 months instead of one every month), and continued in 3. Moreover, the posttransfusional Hb level (7.9 + 0.8 g/dl) we observed in our children affected with thalassemia
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From major is in fact within the target range defined in Algeria, but is under the generally recommended post-transfusional Hb level in countries with sufficient blood supplies.
However, we think it is important to emphasize that in some patients affected with severethalassemia, HU raises total Hb levels while being well tolerated, at least in short-andmedium-term use, and may represent a useful alternative to erythrocyte transfusions.
